COPD 및 천식 치료 시장 규모, 점유율, 동향 분석 : 약제 클래스별, 디바이스/제품별, 기술/소프트웨어별, 적응증별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

COPD & Asthma Therapeutics Market Trends:

The global COPD and asthma therapeutics market size was valued at USD 92.30 billion in 2024 and is expected to grow at a CAGR of 9.18% from 2025 to 2030. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• Bronchodilators
• Corticosteroids
• Leukotriene Modifiers
• Anti-IgE and Anti-IL Monoclonal Antibodies
• Combination Therapy
• Others
• Device/Product Outlook (Revenue, USD Million, 2018 - 2030)
• Inhalers
  • Dry Powder Inhalers (DPI)
  • Metered Dose Inhalers (MDI)
  • Soft Mist Inhalers (SMI)
• Nebulizers
  • Jet
  • Mesh
  • Ultrasonic
• Oxygen Therapy Devices
• Technology/Software Outlook (Revenue, USD Million, 2018 - 2030)
• Smart Inhalers with Bluetooth Connectivity
• AI-based Respiratory Monitoring Platforms
• Mobile Apps for Symptom Tracking
• Digital Adherence and Reminder Systems
• Telepulmonology Solutions
• Indication Outlook (Revenue, USD Million, 2018 - 2030)
• Asthma
• COPD
• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Device/Product
  • 1.2.3. Technology/Software
  • 1.2.4. Indication
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Emergence of novel biologics
    • 3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.
    • 3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.
    • 3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.
    • 3.2.2.2. High cost of biologics and advanced therapies
  • 3.2.3. Industry Opportunity Analysis
  • 3.2.4. Industry Challenge Analysis
  • 3.2.5. Case Studies
• 3.3. Business Environment Analysis
  • 3.3.1. Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis
• 3.4. COVID-19 Impact Analysis

Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. Drug Class Market Share Movement Analysis, 2024 & 2030
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 4.3.1. Bronchodilators
    • 4.3.1.1. Bronchodilators market, 2018 - 2030 (USD Million)
  • 4.3.2. Corticosteroids
    • 4.3.2.1. Corticosteroids market, 2018 - 2030 (USD Million)
  • 4.3.3. Leukotriene Modifiers
    • 4.3.3.1. Leukotriene Modifiers market, 2018 - 2030 (USD Million)
  • 4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies
    • 4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018 - 2030 (USD Million)
  • 4.3.5. Combination Therapy
    • 4.3.5.1. Combination Therapy market, 2018 - 2030 (USD Million)
  • 4.3.6. Others
    • 4.3.6.1. Others market, 2018 - 2030 (USD Million)

Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis

• 5.1. Device/Product Dashboard
• 5.2. Device/Product Market Share Movement Analysis, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)
• 5.4. Inhalers
  • 5.4.1. Inhalers market, 2018 - 2030 (USD Million)
    • 5.4.1.1. Dry Powder Inhalers
    • 5.4.1.1.1.Dry Powder Inhalers market, 2018 - 2030 (USD Million)
    • 5.4.1.2. Metered Dose Inhalers
    • 5.4.1.2.1.Metered Dose Inhalers market, 2018 - 2030 (USD Million)
    • 5.4.1.3. Soft Mist Inhalers
    • 5.4.1.3.1.Soft Mist Inhalers market, 2018 - 2030 (USD Million)
• 5.5. Nebulizers
  • 5.5.1. Nebulizers market, 2018 - 2030 (USD Million)
    • 5.5.1.1. Jet nebulizers
      • 5.5.1.1.1. Jet nebulizers market, 2018 - 2030 (USD Million)
    • 5.5.1.2. Mesh nebulizers
      • 5.5.1.2.1. Mesh nebulizers market, 2018 - 2030 (USD Million)
    • 5.5.1.3. Ultrasonic
      • 5.5.1.3.1. Ultrasonic Inhalers market, 2018 - 2030 (USD Million)
• 5.6. Oxygen Therapy Devices
  • 5.6.1. Oxygen Therapy Devices market, 2018 - 2030 (USD Million)

Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis

• 6.1. Technology/Software Segment Dashboard
• 6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)
• 6.4. Smart Inhalers with Bluetooth Connectivity
  • 6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018 - 2030 (USD Million)
• 6.5. AI-based Respiratory Monitoring Platforms
  • 6.5.1. AI-based Respiratory Monitoring Platforms market, 2018 - 2030 (USD Million)
• 6.6. Mobile Apps for Symptom Tracking
  • 6.6.1. Mobile Apps for Symptom Tracking market, 2018 - 2030 (USD Million)
• 6.7. Digital Adherence and Reminder Systems
  • 6.7.1. Digital Adherence and Reminder Systems market, 2018 - 2030 (USD Million)
• 6.8. Telepulmonology Solutions
  • 6.8.1. Telepulmonology Solutions market, 2018 - 2030 (USD Million)

Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis

• 7.1. Indication Segment Dashboard
• 7.2. Indication Market Share Movement Analysis, 2024 & 2030
• 7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 7.4. Asthma
  • 7.4.1. Asthma market, 2018 - 2030 (USD Million)
• 7.5. COPD
  • 7.5.1. COPD market, 2018 - 2030 (USD Million)

Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis

• 8.1. Distribution Channel Segment Dashboard
• 8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030
• 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies market, 2018 - 2030 (USD Million)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies market, 2018 - 2030 (USD Million)
• 8.6. Online Pharmacies
  • 8.6.1. Drug Stores market, 2018 - 2030 (USD Million)

Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market: Key Takeaways
• 9.3. North America
  • 9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. U.S.
    • 9.3.2.1. Key country dynamic
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive insights
    • 9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key country dynamic
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive insights
    • 9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key country dynamic
    • 9.3.4.2. Regulatory framework
    • 9.3.4.3. Competitive insights
    • 9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamic
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive insights
    • 9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. UK
    • 9.4.3.1. Key country dynamic
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive insights
    • 9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key country dynamic
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive insights
    • 9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key country dynamic
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive insights
    • 9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key country dynamic
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive insights
    • 9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key country dynamic
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive insights
    • 9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key country dynamic
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive insights
    • 9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key country dynamic
    • 9.4.9.2. Regulatory framework
    • 9.4.9.3. Competitive insights
    • 9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key country dynamic
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive insights
    • 9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key country dynamic
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive insights
    • 9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key country dynamic
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive insights
    • 9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamic
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive insights
    • 9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.6. Australia
    • 9.5.6.1. Key country dynamic
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive insights
    • 9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.5.7. Thailand
    • 9.5.7.1. Key country dynamic
    • 9.5.7.2. Regulatory framework
    • 9.5.7.3. Competitive insights
    • 9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key country dynamic
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive insights
    • 9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key country dynamic
    • 9.6.3.2. Regulatory framework
    • 9.6.3.3. Competitive insights
    • 9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key country dynamic
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive insights
    • 9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key country dynamic
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive insights
    • 9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key country dynamic
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive insights
    • 9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key country dynamic
    • 9.7.5.2. Regulatory framework
    • 9.7.5.3. Competitive insights
    • 9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Teva Pharmaceutical Industries Ltd.
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial performance
    • 10.5.1.3. Product benchmarking
    • 10.5.1.4. Strategic initiatives
  • 10.5.2. GSK plc
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial performance
    • 10.5.2.3. Product benchmarking
    • 10.5.2.4. Strategic initiatives
  • 10.5.3. Merck & Co., Inc.
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial performance
    • 10.5.3.3. Product benchmarking
    • 10.5.3.4. Strategic initiatives
  • 10.5.4. F. Hoffmann-La Roche Ltd
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial performance
    • 10.5.4.3. Product benchmarking
    • 10.5.4.4. Strategic initiatives
  • 10.5.5. AstraZeneca
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial performance
    • 10.5.5.3. Product benchmarking
    • 10.5.5.4. Strategic initiatives
  • 10.5.6. Boehringer Ingelheim International GmbH
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial performance
    • 10.5.6.3. Product benchmarking
    • 10.5.6.4. Strategic initiatives
  • 10.5.7. Sanofi
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial performance
    • 10.5.7.3. Product benchmarking
    • 10.5.7.4. Strategic initiatives
  • 10.5.8. Koninklijke Philips N.V.
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial performance
    • 10.5.8.3. Product benchmarking
    • 10.5.8.4. Strategic initiatives
  • 10.5.9. BD
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial performance
    • 10.5.9.3. Product benchmarking
  • 10.5.10. Covis Pharma
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial performance
    • 10.5.10.3. Product benchmarking
  • 10.5.11. Findair Sp. z o. o.
    • 10.5.11.1. Overview
    • 10.5.11.2. Financial performance
    • 10.5.11.3. Product benchmarking
  • 10.5.12. Novartis AG
    • 10.5.12.1. Overview
    • 10.5.12.2. Financial performance
    • 10.5.12.3. Product benchmarking
  • 10.5.13. F. Hoffmann-La Roche Ltd
    • 10.5.13.1. Overview
    • 10.5.13.2. Financial performance
    • 10.5.13.3. Product benchmarking
  • 10.5.14. Cipla Ltd.
    • 10.5.14.1. Overview
    • 10.5.14.2. Financial performance
    • 10.5.14.3. Product benchmarking
  • 10.5.15. Chiesi Air
    • 10.5.15.1. Overview
    • 10.5.15.2. Financial performance
    • 10.5.15.3. Product benchmarking